barusiban
Modify Date: 2024-01-03 14:22:14
barusiban structure
|
Common Name | barusiban | ||
|---|---|---|---|---|
| CAS Number | 285571-64-4 | Molecular Weight | 830.04900 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C40H63N9O8S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of barusibanBarusiban (FE-200440) is an oxytocin receptor (OT-R) antagonist (Ki=0.8 nM), inhibits OT-induced contraction. Barusiban can be used in preterm labor (PTL), in vitro fertilisation (IVF) and infertility research[1][2][3]. |
| Name | (4S,7S,10S,16R)-N-[(2S)-5-amino-1-hydroxypentan-2-yl]-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-10-[(2R)-butan-2-yl]-16-(1H-indol-3-ylmethyl)-N-methyl-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentazacycloicosane-4-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | Barusiban (FE-200440) is an oxytocin receptor (OT-R) antagonist (Ki=0.8 nM), inhibits OT-induced contraction. Barusiban can be used in preterm labor (PTL), in vitro fertilisation (IVF) and infertility research[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Barusiban shows affinity for oxytocin receptor (Ki=0.8 nM) in COS cells expressed with oxytocin receptor[3]. |
| In Vivo | Barusiban (intravenous injection; 50 or 150 μg/kg; once) treatment shows inhibition on OT-induced contractions[2]. Animal Model: Pregnant cynomolgus monkeys injected with oxytocin (OT)[2] Dosage: 50 or 150 μg/kg Administration: Intravenous injection; 50 or 150 μg/kg; once Result: Reduced uterine contractions to baseline levels effectively. Reduced intrauterine pressure (IUP) from 6-7.5 kmm Hg•h to approximately 1 kmm Hg•h. |
| Molecular Formula | C40H63N9O8S |
|---|---|
| Molecular Weight | 830.04900 |
| Exact Mass | 829.45200 |
| PSA | 314.68000 |
| LogP | 3.41670 |
| FE200 440 |
| Barusiban [INN] |
| UNII-UX33I93GLS |
| Barusiban |
| C4.6,S1-Cyclo(N-(3-sulfanylpropanoyl)-D-tryptophyl-L-isoleucyl-L-alloisoleucyl-L-asparaginyl-L-2-aminobutanoyl-N-methyl-L-ornithinol) |